NO2498610T3 - - Google Patents

Info

Publication number
NO2498610T3
NO2498610T3 NO10830880A NO10830880A NO2498610T3 NO 2498610 T3 NO2498610 T3 NO 2498610T3 NO 10830880 A NO10830880 A NO 10830880A NO 10830880 A NO10830880 A NO 10830880A NO 2498610 T3 NO2498610 T3 NO 2498610T3
Authority
NO
Norway
Application number
NO10830880A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2498610(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2498610T3 publication Critical patent/NO2498610T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Transplantation (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10830880A 2009-11-13 2010-11-15 NO2498610T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (1)

Publication Number Publication Date
NO2498610T3 true NO2498610T3 (cg-RX-API-DMAC7.html) 2018-08-11

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10830880A NO2498610T3 (cg-RX-API-DMAC7.html) 2009-11-13 2010-11-15
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2020039C NO2020039I1 (no) 2009-11-13 2020-11-18 Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid

Country Status (32)

Country Link
US (4) US8362048B2 (cg-RX-API-DMAC7.html)
EP (3) EP3868377A1 (cg-RX-API-DMAC7.html)
JP (3) JP5650233B2 (cg-RX-API-DMAC7.html)
KR (2) KR101721716B1 (cg-RX-API-DMAC7.html)
CN (2) CN102762100B (cg-RX-API-DMAC7.html)
AU (1) AU2010319983B2 (cg-RX-API-DMAC7.html)
BR (2) BR122018077504B8 (cg-RX-API-DMAC7.html)
CA (2) CA2986521C (cg-RX-API-DMAC7.html)
CY (3) CY1120338T1 (cg-RX-API-DMAC7.html)
DK (2) DK3406142T3 (cg-RX-API-DMAC7.html)
EA (2) EA024801B1 (cg-RX-API-DMAC7.html)
ES (2) ES2858337T3 (cg-RX-API-DMAC7.html)
FI (1) FI2498610T4 (cg-RX-API-DMAC7.html)
FR (1) FR20C1059I2 (cg-RX-API-DMAC7.html)
HR (2) HRP20180874T4 (cg-RX-API-DMAC7.html)
HU (3) HUE037535T2 (cg-RX-API-DMAC7.html)
IL (2) IL219691B (cg-RX-API-DMAC7.html)
LT (3) LT3406142T (cg-RX-API-DMAC7.html)
LU (1) LUC00184I2 (cg-RX-API-DMAC7.html)
MX (1) MX2012005560A (cg-RX-API-DMAC7.html)
MY (2) MY161854A (cg-RX-API-DMAC7.html)
NO (2) NO2498610T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ599915A (cg-RX-API-DMAC7.html)
PH (2) PH12012500939A1 (cg-RX-API-DMAC7.html)
PL (2) PL3406142T3 (cg-RX-API-DMAC7.html)
PT (2) PT2498610T (cg-RX-API-DMAC7.html)
RS (2) RS57253B2 (cg-RX-API-DMAC7.html)
SG (1) SG10201407357PA (cg-RX-API-DMAC7.html)
SI (2) SI3406142T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800288T1 (cg-RX-API-DMAC7.html)
TR (1) TR201807912T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011060392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161854A (en) 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
RS57070B1 (sr) 2009-11-13 2018-06-29 Celgene Int Ii Sarl Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
CA2877097C (en) * 2012-06-21 2018-08-07 Eisai R&D Management Co., Ltd. Novel indanesulfamide derivative
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
EP3062792A1 (en) * 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
AU2016246398A1 (en) 2015-04-06 2017-10-26 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
EP3470400B1 (en) * 2016-06-14 2025-04-02 Receptos LLC Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
BR112019001153A2 (pt) * 2016-07-22 2019-04-30 Shijiazhuang Sagacity New Drug Development Co., Ltd. agonista s1p1 e aplicação do mesmo
CN109563059A (zh) 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
WO2018050091A1 (zh) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
US10981900B2 (en) * 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
US20200031784A1 (en) * 2017-04-07 2020-01-30 Solipharma Llc Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
US11207301B2 (en) 2017-05-08 2021-12-28 Receptos Llc Sphingosine 1 phosphate receptor agonists for neuroprotection
EA201992421A1 (ru) * 2017-05-22 2020-03-27 Эгиш Дьёдьсердьяр Зрт. Способ получения озанимода
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
CN110944982A (zh) * 2017-08-31 2020-03-31 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
WO2019141245A1 (zh) * 2018-01-18 2019-07-25 南京明德新药研发股份有限公司 一种三并环化合物的晶型、盐型及其制备方法
KR20200132858A (ko) 2018-03-20 2020-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 간질 치료제
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
WO2020005313A1 (en) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20210340115A1 (en) 2018-09-12 2021-11-04 Pharmazell Gmbh A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
MX2021006692A (es) 2018-12-07 2021-07-07 Synthon Bv Proceso mejorado para preparar ozanimod.
EP3947363A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS
JP2022528001A (ja) * 2019-03-29 2022-06-07 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
KR20210150371A (ko) * 2019-03-29 2021-12-10 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
EP3959204A4 (en) * 2019-04-26 2022-12-28 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
EP3999495A1 (en) 2019-07-16 2022-05-25 Synthon B.V. Improved process for preparing ozanimod
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
JP2023509698A (ja) * 2020-01-06 2023-03-09 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連した状態の処置方法
EP4116294B1 (en) * 2020-03-04 2025-09-03 Helioeast Pharmaceutical Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
EP4116295A4 (en) * 2020-03-04 2023-08-02 Helioeast Pharmaceutical Co., Ltd. TRICYCLIC COMPOUNDS AND THEIR USE
US11723895B2 (en) 2020-03-17 2023-08-15 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
EP4126829A1 (en) * 2020-03-27 2023-02-08 Receptos Llc Sphingosine 1 phosphate receptor modulators
US12428386B2 (en) * 2020-03-27 2025-09-30 Receptos Llc Sphingosine 1 phosphate receptor modulators
EP4126826A1 (en) 2020-04-02 2023-02-08 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
JP7738667B2 (ja) * 2021-04-09 2025-09-12 ヒーリオイースト ファーマシューティカル カンパニー リミテッド オキサジアゾール置換スピロ環系化合物とその使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
CN121194965A (zh) 2023-05-31 2025-12-23 奎米卡新特缇卡股份有限公司 盐酸奥扎莫德的无定形形式和晶型
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
AU1886892A (en) 1991-04-12 1992-11-17 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
NZ505599A (en) * 1998-01-23 2003-06-30 Sankyo Co Morpholino alkyl substituted spiropiperidine derivatives useful as tachykinin receptor antagonists
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2509218C (en) * 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
EP3889142B1 (en) 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
JP2007528872A (ja) * 2003-10-01 2007-10-18 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
CA2600008A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
AU2006278718B2 (en) † 2005-08-03 2010-10-07 Secura Bio Inc. Use of HDAC inhibitors for the treatment of myeloma
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
EP1963509A4 (en) 2005-12-21 2009-07-29 Joseph Gabriele CATECHOLAMINE-REGULATED PROTEIN
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
KR20090051774A (ko) * 2006-09-21 2009-05-22 액테리온 파마슈티칼 리미티드 페닐 유도체 및 면역조절제로서 이들의 용도
CA2669104A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
KR20090095648A (ko) 2006-12-15 2009-09-09 아보트 러보러터리즈 신규한 옥사디아졸 화합물
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106204A1 (en) 2007-02-28 2008-09-04 Rib-X-Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
MY156381A (en) * 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
WO2009151259A1 (ko) * 2008-06-13 2009-12-17 두원공과대학교 로터리 밸브를 구비한 왕복동 압축기
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
RS57070B1 (sr) 2009-11-13 2018-06-29 Celgene Int Ii Sarl Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
MY161854A (en) 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EA025672B1 (ru) 2009-11-13 2017-01-30 Рецептос Ллк Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

Also Published As

Publication number Publication date
JP2015038145A (ja) 2015-02-26
BR112012011427B1 (pt) 2021-04-20
AU2010319983B2 (en) 2015-03-12
EA201690391A1 (ru) 2016-08-31
FR20C1059I2 (fr) 2021-12-10
CN102762100A (zh) 2012-10-31
PL3406142T3 (pl) 2021-08-30
CA2986521C (en) 2020-06-30
MX2012005560A (es) 2012-10-05
US10239846B2 (en) 2019-03-26
CA2986521A1 (en) 2011-05-19
HUE037535T2 (hu) 2018-09-28
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05
DK2498610T3 (en) 2018-06-14
EA024801B1 (ru) 2016-10-31
SG10201407357PA (en) 2014-12-30
PT2498610T (pt) 2018-06-19
EA201290323A1 (ru) 2013-05-30
CN105061350A (zh) 2015-11-18
IL219691B (en) 2019-07-31
NO2020039I1 (no) 2020-11-18
EP3868377A1 (en) 2021-08-25
SI2498610T2 (sl) 2024-10-30
EP3406142B8 (en) 2021-03-03
US20110172202A1 (en) 2011-07-14
SI2498610T1 (en) 2018-07-31
FI2498610T4 (fi) 2024-08-29
RS57253B2 (sr) 2024-10-31
SI3406142T1 (sl) 2021-08-31
US9388147B2 (en) 2016-07-12
EP2498610B2 (en) 2024-06-19
PL2498610T3 (pl) 2018-08-31
US20170320839A1 (en) 2017-11-09
IL267956A (en) 2019-09-26
ES2858337T3 (es) 2021-09-30
ES2673160T5 (es) 2024-11-19
SMT202100169T1 (it) 2021-07-12
JP2013510885A (ja) 2013-03-28
LUC00184I2 (cg-RX-API-DMAC7.html) 2024-07-01
KR20120102704A (ko) 2012-09-18
HUE054000T2 (hu) 2021-08-30
CN102762100B (zh) 2015-07-01
CA2780772C (en) 2018-01-16
MY189750A (en) 2022-03-02
TR201807912T4 (tr) 2018-06-21
BR122018077504B1 (pt) 2021-05-11
PH12015502708B1 (en) 2018-06-06
CY2020035I1 (el) 2021-03-12
US8362048B2 (en) 2013-01-29
KR20160149317A (ko) 2016-12-27
EP2498610A1 (en) 2012-09-19
EP2498610A4 (en) 2013-05-22
HK1213874A1 (zh) 2016-07-15
JP5982705B2 (ja) 2016-08-31
HRP20210446T1 (hr) 2021-05-14
PH12015502708A1 (en) 2016-10-17
HRP20180874T1 (hr) 2018-07-13
BR122018077504B8 (pt) 2021-05-25
BR112012011427B8 (pt) 2021-05-25
EP2498610B1 (en) 2018-03-14
WO2011060392A1 (en) 2011-05-19
CA2780772A1 (en) 2011-05-19
MY161854A (en) 2017-05-15
PL2498610T5 (pl) 2024-11-04
BR112012011427A2 (pt) 2015-10-06
HRP20180874T4 (hr) 2024-09-27
PH12012500939A1 (en) 2016-06-15
KR101721716B1 (ko) 2017-04-10
KR101752124B1 (ko) 2017-06-28
LTPA2020533I1 (lt) 2020-12-10
PT3406142T (pt) 2021-03-26
DK2498610T4 (da) 2024-09-09
FR20C1059I1 (cg-RX-API-DMAC7.html) 2020-12-25
HUS2000045I1 (hu) 2020-12-28
LTC2498610I2 (lt) 2022-06-10
AU2010319983A1 (en) 2012-05-31
EP3406142A1 (en) 2018-11-28
EA035768B1 (ru) 2020-08-07
CY1120338T1 (el) 2019-07-10
CY2020035I2 (el) 2021-03-12
JP5650233B2 (ja) 2015-01-07
CY1124121T1 (el) 2022-05-27
DK3406142T3 (da) 2021-03-22
CN105061350B (zh) 2018-05-29
EP3406142B1 (en) 2020-12-23
SMT201800288T1 (it) 2018-07-17
RS61829B1 (sr) 2021-06-30
AU2010319983A2 (en) 2013-09-12
NZ599915A (en) 2014-07-25
LT3406142T (lt) 2021-06-10
ES2673160T3 (es) 2018-06-20
US20150299149A1 (en) 2015-10-22
LT2498610T (lt) 2018-06-11
IL219691A0 (en) 2012-07-31
IL267956B (en) 2021-01-31
HK1175948A1 (en) 2013-07-19
JP2014122208A (ja) 2014-07-03

Similar Documents

Publication Publication Date Title
LUC00184I2 (cg-RX-API-DMAC7.html)
BRPI0925311A2 (cg-RX-API-DMAC7.html)
BR112012008195A2 (cg-RX-API-DMAC7.html)
BRPI0924307A2 (cg-RX-API-DMAC7.html)
BR112012008267A2 (cg-RX-API-DMAC7.html)
BR112012012396A2 (cg-RX-API-DMAC7.html)
BR122021004633A2 (cg-RX-API-DMAC7.html)
BR112012003080A2 (cg-RX-API-DMAC7.html)
BR112012012487A2 (cg-RX-API-DMAC7.html)
BR122017024704A2 (cg-RX-API-DMAC7.html)
BR112012012080A2 (cg-RX-API-DMAC7.html)
BR112012009797A2 (cg-RX-API-DMAC7.html)
BR112012009446A2 (cg-RX-API-DMAC7.html)
BR112012009703A2 (cg-RX-API-DMAC7.html)
BRPI0924534A2 (cg-RX-API-DMAC7.html)
BR112012010357A2 (cg-RX-API-DMAC7.html)
BR112012007656A2 (cg-RX-API-DMAC7.html)
BR122019005883A2 (cg-RX-API-DMAC7.html)
BR112012001263A2 (cg-RX-API-DMAC7.html)
BR112012014856A2 (cg-RX-API-DMAC7.html)
BR112012002627A2 (cg-RX-API-DMAC7.html)
BR112012007654A2 (cg-RX-API-DMAC7.html)
BR112012005951A2 (cg-RX-API-DMAC7.html)
BR112012007672A2 (cg-RX-API-DMAC7.html)
BR112012007671A2 (cg-RX-API-DMAC7.html)